PULSE BIOSCIENCES INC

The stock of Pulse Biosciences hit a new all-time high of $56.15 and has posted strong gains over the past year. Despite reporting a higher-than-expected adjusted loss of $0.36 per share and revenues of $400,000 for the second quarter, investors were optimistic due to faster patient recruitment in the atrial fibrillation study and progress in the thyroid and surgical programs. Analysts remain positive: Freedom Kapital and Needham initiated buy ratings with price targets of $73 and $58, respectively, and Canaccord raised its target to $43. The rally underscores confidence in the company’s nsPFA/pulsed-field ablation platform. » More on de.investing.com

Pulse Biosciences is developing a patented nanosecond pulsed field ablation, a non‑thermal method to selectively destroy diseased cells without damaging surrounding tissue. After selling the CellFX consoles, the company generates steady revenue from disposable medical supplies and usage‑based software fees with high gross margins. A planned push into a multibillion‑dollar market is expected to further accelerate growth. » More on finanzen.net

Pulse Biosciences reports advances in clinical trials for its very-short electrical pulse technology, intended for uses including cardiology and thyroid diseases. The company continues to invest in studies, regulatory approvals and expansion of its product platform and is in an early commercialization phase, making regulatory approval now more likely. » More on finanzen.net